Jatenzo and Rosuvastatin Interaction: What You Need to Know

What the Drug Interaction Actually Is

Jatenzo and rosuvastatin can interact through a shared hepatic transporter called OATP1B1 (organic anion transporting polypeptide 1B1), and to a lesser extent OATP1B3. Rosuvastatin depends heavily on these transporters to enter liver cells and be cleared from circulation. When a co-administered drug reduces OATP1B1 activity, rosuvastatin plasma concentrations rise, which amplifies both the lipid-lowering effect and the risk of skeletal muscle toxicity.

How OATP1B1 Works

OATP1B1 is encoded by the SLCO1B1 gene and expressed on the sinusoidal membrane of hepatocytes. It is responsible for extracting multiple drugs from portal blood into the liver for metabolism or biliary excretion. Rosuvastatin is an OATP1B1 substrate with approximately 88% of its hepatic uptake mediated by this transporter [1]. Drugs that block OATP1B1 can more than double rosuvastatin area under the curve (AUC), as demonstrated with cyclosporine, which raised rosuvastatin AUC by 610% in pharmacokinetic studies [2].

Where Testosterone Fits In

Testosterone and its metabolites have been identified as inhibitors of OATP1B1 and OATP1B3 in in-vitro transporter assays. A 2015 study published in the British Journal of Pharmacology showed that testosterone sulfate and other androgen conjugates inhibit OATP1B1-mediated transport at concentrations achievable in portal circulation [3]. Oral testosterone undecanoate (Jatenzo) is absorbed via intestinal lymphatics, bypassing first-pass hepatic metabolism, which means systemic testosterone levels after each dose can reach pharmacologically significant concentrations. Those concentrations may be sufficient to produce clinically relevant OATP1B1 inhibition in some patients.

The FDA prescribing information for Jatenzo notes that testosterone is a substrate and potential inhibitor of the P-glycoprotein (P-gp) transporter as well, adding a secondary pathway through which statin exposure could be altered [4].

Severity and Clinical Significance

The interaction is classified as moderate in standard drug-drug interaction (DDI) databases, including Lexicomp and Drugs.com. A moderate classification means the combination is not absolutely contraindicated, but it requires attention. Prescribers should not simply co-prescribe and forget.

What "Moderate" Means in Practice

A moderate DDI classification places Jatenzo plus rosuvastatin in the same category as diltiazem plus simvastatin. The clinical outcome depends on:

• The rosuvastatin dose (higher doses carry more muscle risk at any given AUC elevation)
• The patient's SLCO1B1 genotype (loss-of-function variants amplify statin plasma levels independently)
• Concurrent medications that also inhibit OATP1B1 (cyclosporine, gemfibrozil, atazanavir)
• Renal function, since rosuvastatin is approximately 90% renally excreted and CKD already increases statin exposure [5]

The 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease states: "Clinicians should consider statin-drug interactions before prescribing and recognize that interactions may increase statin adverse effects." [6] That language applies directly here.

Myopathy Risk Numbers

Statin-associated muscle symptoms (SAMS) occur in roughly 5-10% of statin users in randomized trials, though observational data suggest rates up to 29% in real-world practice [7]. Rhabdomyolysis, the most severe form, is rare but life-threatening, occurring at approximately 1-3 per 100,000 patient-years across statin users. Any drug that raises statin exposure shifts these probabilities upward, particularly in patients already at higher baseline muscle risk.

Mechanism in Full Detail

CYP450 Pathway Contributions

Rosuvastatin is minimally metabolized by CYP2C9 (producing the N-desmethyl metabolite, which accounts for roughly 10% of circulating drug-related material). Testosterone itself is primarily metabolized by CYP3A4. Neither drug is a major inhibitor of the other's CYP-mediated elimination, so the CYP450 pathway contributes little to this specific DDI.

P-Glycoprotein

The Jatenzo FDA label identifies testosterone as a P-gp inhibitor [4]. Rosuvastatin is a known P-gp substrate in intestinal efflux, though the clinical magnitude of P-gp inhibition on rosuvastatin bioavailability is considered small compared with OATP1B1 effects. P-gp inhibition may increase rosuvastatin intestinal absorption slightly, adding a secondary pharmacokinetic pressure in the same direction as OATP1B1 inhibition.

Pharmacodynamic Interaction

Beyond pharmacokinetics, testosterone and rosuvastatin share opposing effects on certain lipid parameters. Testosterone therapy tends to lower HDL cholesterol (by roughly 4-10% across clinical studies), while rosuvastatin raises HDL [8]. The net lipid effect in a patient taking both drugs may be blunted HDL improvement, which is relevant to cardiovascular risk management but is not a toxicity concern in the conventional sense.

Testosterone also tends to reduce total cholesterol and LDL modestly, so the LDL-lowering effect of rosuvastatin may appear numerically smaller in the context of TRT, even if the statin is working as expected at the hepatic level.

Jatenzo-Specific Factors That Matter

Jatenzo is not pharmacologically identical to other testosterone formulations, and those differences affect how this interaction plays out.

Lymphatic Absorption

Oral testosterone undecanoate is formulated in a lipid vehicle and absorbed through intestinal lymphatics rather than portal blood. This design produces a high peak testosterone concentration (Cmax) in systemic circulation approximately 2-3 hours after each dose [4]. That post-absorption peak is when OATP1B1 inhibition would be most pronounced. Patients who take rosuvastatin at the same time as a Jatenzo dose may experience a more substantial transient rise in rosuvastatin plasma levels than patients who separate the doses by several hours.

Cardiovascular Safety Label

The Jatenzo label carries an FDA-required warning about blood pressure increases. In the key Phase 3 trial supporting Jatenzo approval, 21% of patients required new antihypertensive therapy or dose escalation of existing antihypertensives during the study period [4]. Elevated blood pressure compounds cardiovascular risk in patients already managing dyslipidemia, which is exactly the population most likely to be on rosuvastatin. Prescribers must weigh this cumulative cardiovascular burden.

Dose Range

Jatenzo is started at 237 mg twice daily and titrated to 158 mg or 396 mg based on mid-morning serum testosterone levels. Higher doses produce higher systemic testosterone exposure, and theoretically greater OATP1B1 inhibitory pressure. Patients titrated to 396 mg twice daily may carry more interaction risk than those maintained on 158 mg twice daily, though head-to-head interaction data at different Jatenzo doses have not been published.

Monitoring Protocol

The following monitoring framework is derived from FDA labeling for both drugs, the 2019 ACC/AHA statin safety recommendations, and the Endocrine Society's 2018 testosterone therapy guidelines [6, 9].

Before Starting the Combination

1. Obtain a baseline lipid panel (total cholesterol, LDL, HDL, triglycerides).
2. Measure serum creatine kinase (CK).
3. Record baseline serum creatinine and estimated GFR (eGFR), since CKD amplifies rosuvastatin exposure.
4. Review the full medication list for additional OATP1B1 inhibitors (cyclosporine, gemfibrozil, niacin greater than 1 g/day, protease inhibitors).
5. Ask about personal or family history of statin-associated myopathy, hypothyroidism, or alcohol use disorder, all of which independently raise myopathy risk.
6. Confirm cardiovascular risk score (ASCVD 10-year risk or equivalent) to validate the statin indication and appropriate dose tier.

First 3 Months

• Recheck serum testosterone (mid-morning, 6 hours post-dose) at 3 weeks to guide Jatenzo dose titration.
• Repeat lipid panel and CK at 6-8 weeks.
• Monitor blood pressure at every contact, given the Jatenzo hypertension warning.
• Ask specifically about new muscle pain, weakness, or brown-colored urine at each visit.

Ongoing Monitoring

• Lipid panel every 3 months for the first year, then every 6-12 months if stable.
• CK at each lipid check or immediately if the patient reports muscle symptoms.
• If CK exceeds 5 times the upper limit of normal without an alternative explanation, hold rosuvastatin and reassess.
• If CK exceeds 10 times the upper limit of normal or the patient has myoglobinuria, discontinue rosuvastatin immediately and evaluate for rhabdomyolysis.

Dose Adjustment Considerations

No fixed dose-adjustment formula exists specifically for the Jatenzo-rosuvastatin combination, because prospective pharmacokinetic studies measuring the magnitude of rosuvastatin AUC change with Jatenzo have not been conducted and published as of this writing.

Practical Rosuvastatin Dosing

The FDA rosuvastatin label recommends capping the dose at 10 mg/day in patients taking cyclosporine (a potent OATP1B1 inhibitor) and at 20 mg/day in patients on atazanavir or lopinavir/ritonavir [10]. Testosterone's OATP1B1 inhibitory potency in vivo is almost certainly lower than cyclosporine's. A reasonable clinical default is to use the lowest rosuvastatin dose that achieves the patient's LDL target, with a maximum of 20 mg/day while the patient remains on Jatenzo. If the patient requires 40 mg rosuvastatin to reach goal LDL, discuss whether an alternative statin with less OATP1B1 dependence (such as pravastatin or fluvastatin) might be substituted.

Timing Separation

Because Jatenzo produces a Cmax spike roughly 2-3 hours post-dose and is taken twice daily with meals, patients may reduce peak transporter inhibition by taking rosuvastatin at bedtime rather than with morning or evening Jatenzo doses. This has not been studied in a controlled trial for this specific combination, but it is a low-risk, practical strategy consistent with managing other transporter-based interactions.

Alternative Statins to Consider

Not all statins rely equally on OATP1B1 for hepatic uptake, and switching may be appropriate in some patients.

Lower-Dependence Options

• Pravastatin relies on OATP1B1 for approximately 40% of its hepatic uptake, considerably less than rosuvastatin's 88% dependence [1]. It is also renally cleared and does not require CYP450 metabolism, making it one of the lower-interaction statins overall.
• Fluvastatin is primarily CYP2C9-metabolized with modest OATP1B1 involvement. It may be a reasonable alternative for patients who experience myopathy on rosuvastatin plus Jatenzo.
• Atorvastatin is an OATP1B1 substrate but is also substantially metabolized by CYP3A4. The net interaction profile with testosterone is similar to rosuvastatin in terms of transporter concerns, so switching to atorvastatin does not eliminate the issue.

Statins to Avoid

Simvastatin and lovastatin are CYP3A4-dependent and carry higher intrinsic myopathy risk unrelated to OATP1B1. Neither is a preferred choice in a patient also taking a P-gp inhibitor. They should generally be avoided in this clinical context regardless of the testosterone formulation.

Patient Counseling Points

Patients on both Jatenzo and rosuvastatin need concrete, specific information, not general reassurance.

What to Tell the Patient

Tell the patient to report any unexplained muscle pain or weakness within 48 hours of onset, without waiting for the next scheduled appointment. Muscle pain that worsens over days, involves weakness (not just soreness), or is accompanied by dark-colored urine requires same-day evaluation because these signs may indicate rhabdomyolysis.

Tell the patient to take Jatenzo with a fat-containing meal as directed, since food is required for adequate lymphatic absorption. Skipping food reduces testosterone absorption, which could paradoxically reduce both therapeutic effect and the transporter interaction, but it is not a recommended strategy for managing the DDI.

Remind the patient to disclose both drugs to any specialist, urgent care provider, or emergency physician, since providers unfamiliar with Jatenzo may not recognize testosterone as an OATP1B1 inhibitor.

"Patients on testosterone therapy who develop unexplained myalgia should have creatine kinase measured promptly, and all concurrent medications that affect statin transport should be reviewed before attributing symptoms to any single cause," states the Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men [9].

Cardiovascular Risk Context

Men with hypogonadism prescribed Jatenzo are a population with elevated cardiovascular risk by baseline characteristics. The TRAVERSE trial (N=5,246, published in the New England Journal of Medicine, 2023) found that testosterone replacement therapy was noninferior to placebo for major adverse cardiovascular events (MACE) over a median of 33 months in men aged 45-80 with hypogonadism and established cardiovascular disease or high cardiovascular risk [11]. That reassurance is meaningful, but TRAVERSE enrolled patients on guideline-directed therapy including statins, and it did not report detailed drug-interaction subgroup analyses.

Rosuvastatin's cardiovascular benefit is substantial and well-established. The JUPITER trial (N=17,802) showed that rosuvastatin 20 mg reduced the rate of first major cardiovascular events by 44% versus placebo in patients with elevated high-sensitivity CRP (hazard ratio 0.56; 95% CI 0.46-0.69; P<0.00001) [12]. Stopping or reducing rosuvastatin to manage a theoretical interaction risk, when the drug is indicated, carries its own harm. The goal is not to choose one drug over the other, but to use both safely with appropriate monitoring.

Summary of Clinical Decision Points

A clinician managing a male patient on Jatenzo who also needs statin therapy should work through four questions in sequence.

First, is rosuvastatin the right statin? If the patient has no prior statin intolerance and rosuvastatin is the preferred agent for his LDL target and risk profile, it remains a reasonable choice with the monitoring framework above.

Second, what rosuvastatin dose is needed? Start at the lowest dose that is likely to achieve the LDL goal. Avoid 40 mg/day while the patient is on Jatenzo unless lower doses are clearly insufficient and the patient has demonstrated good CK tolerance.

Third, are there other OATP1B1 inhibitors on the medication list? Cumulative inhibitor burden is the real risk amplifier. A patient on Jatenzo, cyclosporine, and gemfibrozil simultaneously faces a fundamentally different risk profile than one on Jatenzo alone.

Fourth, is the patient's Jatenzo dose stable? Dose titration periods are the highest-risk windows, because rising testosterone concentrations may increase transporter inhibition in a way that a stable maintenance dose does not.

For patients with CKD stage 3 or worse (eGFR <45 mL/min/1.73 m2), consider capping rosuvastatin at 10 mg/day, since impaired renal clearance already elevates rosuvastatin exposure independent of any transporter effect [5].